Reviewer’s report

Title: Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: A systematic review and meta-analysis

Version: 1 Date: 20 July 2014

Reviewer: Ragy Girgis

Reviewer’s report:

Veale et al. report on a systematic review and meta analysis of RCTs of antipsychotic augmentation of SSRI refractory OCD. They report that the evidence is scant and overall there is no effect, though there are signals for risperidone and aripiprazole (but not olanzapine and quetiapine). They suggest caution when using antipsychotics for OCD and when interpreting the results of their meta analysis.

In general, I found this to be a well written, informative, comprehensive review. There were some difficulties with grammar, punctuation, and flow that can be corrected before publication. The data are clearly presented and the methods are well described. The figures and tables are helpful.

Otherwise, the primary limitations of this review/meta analysis are the limitations of the articles they have reviewed (e.g., small samples sizes, limited trials, unclear definitions of treatment resistance, etc.).

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I have no competing interests.